Vadadustat

Vadadustat
Clinical data
Synonyms	AKB-6548, PG-1016548
ATC code	None;
Identifiers
	IUPAC name 2-([5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino)acetic acid;
CAS Number	1000025-07-9;
PubChem CID	23634441;
ChemSpider	34958379;
UNII	I60W9520VV;
Chemical and physical data
Formula	C14H11ClN2O4
Molar mass	306.701 g/mol
3D model (JSmol)	Interactive image;
	SMILES Oc1cc(cnc1C(=O)NCC(=O)O)c2cccc(Cl)c2;

Vadadustat (INN) (AKB-6548) is a drug which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia secondary to chronic kidney disease.^[1]^[2]^[3]

References

↑ Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90(5):1115-1122. . doi:10.1016/j.kint.2016.07.019. PMID 27650732. Missing or empty |title= (help)
↑ Gupta N, Wish JB. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis. 2017 Jun;69(6):815-826. . doi:10.1053/j.ajkd.2016.12.011. PMID 28242135. Missing or empty |title= (help)
↑ Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol. 2017;45(5):380-388. . doi:10.1159/000464476. PMID 28343225. Missing or empty |title= (help)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.